Carolina P. Schröder

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

Eli Dijkers, Thijs H. Oude Munnink, Jos G. W. Kosterink et al. · Clinical Pharmacology & Therapeutics · 2010 · 792 citations

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge et al. · Nature Medicine · 2018 · 702 citations · Full text

Oncologic Imaging, Pd-l1 Blockade, Medicine +11

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 341 citations · Full text

Breast Oncology, Oncology, Engineering +13

Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

Marlous Arjaans, Thijs H. Oude Munnink, Sjoukje F. Oosting et al. · Cancer Research · 2013 · 118 citations · Full text

Bevacizumab-induced Normalization, Angiogenesis, Blood Vessel Normalization +15

89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft

Thijs H. Oude Munnink, Maarten A. de Korte, Wouter B. Nagengast et al. · European Journal of Cancer · 2009 · 98 citations · Full text

Medicine, Human Tumour Xenograft, Pathology +8